AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

10 months ago

Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of…

NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System 

10 months ago

Potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the…

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

10 months ago

Webcast scheduled for Thursday, June 15 at 8:30am PTIRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:…

IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023

10 months ago

Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel…

Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference

10 months ago

BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

10 months ago

Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical…

Oncotelic Launches PR Chatbot

10 months ago

AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),…

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

10 months ago

Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H.…

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

10 months ago

MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed;…

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

10 months ago

The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn…